Bioverativ Inc (NASDAQ:BIVV) Director Brian S. Posner bought 1,000 shares of Bioverativ stock in a transaction that occurred on Wednesday, August 9th. The stock was purchased at an average cost of $59.19 per share, for a total transaction of $59,190.00. Following the purchase, the director now owns 6,693 shares of the company’s stock, valued at $396,158.67. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Bioverativ Inc (NASDAQ BIVV) traded down 4.33% on Thursday, hitting $56.51. The stock had a trading volume of 1,197,035 shares. The company has a 50 day moving average price of $61.31 and a 200-day moving average price of $55.47. The stock has a market cap of $6.11 billion and a PE ratio of 13.43. Bioverativ Inc has a 12 month low of $41.88 and a 12 month high of $64.41.

Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.71 by $0.17. The firm had revenue of $289.10 million for the quarter, compared to the consensus estimate of $269 million. The business’s revenue for the quarter was up 37.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 earnings per share. On average, equities research analysts anticipate that Bioverativ Inc will post $2.90 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at

A number of research analysts recently commented on BIVV shares. Zacks Investment Research raised Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a research note on Tuesday, July 25th. Cowen and Company raised Bioverativ from a “market perform” rating to an “outperform” rating in a research note on Monday, July 10th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Bioverativ in a research note on Friday, June 30th. Deutsche Bank AG assumed coverage on Bioverativ in a research note on Friday, June 23rd. They set a “hold” rating and a $65.00 price objective on the stock. Finally, Credit Suisse Group raised their price objective on Bioverativ from $45.00 to $47.00 and gave the company an “underperform” rating in a research note on Monday, May 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $60.62.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with's FREE daily email newsletter.